Science

The U.S. Food and Drug Administration (FDA) has approved GOMEKLI™ (mirdametinib), SpringWorks Therapeutics, Inc.’s MEK inhibitor, for the treatment of adult and pediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) that are not amenable to complete resection. SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company […]

The production of energy that powers cells and facilitates their operation depends on mitochondria. On the other hand, disorders like type 2 diabetes are linked to mitochondrial abnormalities. Individuals with this condition are unable to use the insulin their pancreas produces to maintain normal blood sugar levels or create enough […]

Skip to content